Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 32054649
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B, Abildgaard N. Zweegman S, et al. Among authors: knut bojanowska d. Haematologica. 2020 Dec 1;105(12):2879-2882. doi: 10.3324/haematol.2019.240374. Haematologica. 2020. PMID: 33256392 Free PMC article. Clinical Trial. No abstract available.
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.
Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E, Wålinder G, Knut-Bojanowska D, Zang C, Turesson I; Real-World Evidence Group within the Nordic Myeloma Study Group (NMSG). Blimark CH, et al. Among authors: knut bojanowska d. Eur J Haematol. 2022 Feb;108(2):99-108. doi: 10.1111/ejh.13707. Epub 2021 Sep 23. Eur J Haematol. 2022. PMID: 34514635
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.
Wålinder G, Genell A, Juliusson G, Svensson R, Santamaria AI, Crafoord J, Carlson K, Knut-Bojanowska D, Veskovski L, Lauri B, Lund J, Turesson I, Hansson M, Blimark CH, Nahi H. Wålinder G, et al. Among authors: knut bojanowska d. Cancer Rep (Hoboken). 2022 Nov;5(11):e1614. doi: 10.1002/cnr2.1614. Epub 2022 Mar 3. Cancer Rep (Hoboken). 2022. PMID: 35243814 Free PMC article.
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MBL, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NWCJ, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S. Groen K, et al. Among authors: knut bojanowska d. Hemasphere. 2023 Aug 30;7(9):e940. doi: 10.1097/HS9.0000000000000940. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37663673 Free PMC article. No abstract available.
Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry.
Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, Knut-Bojanowska D, Larfors G, Turesson I, Villegas-Scivetti M, Sverrisdóttir I. Blimark CH, et al. Among authors: knut bojanowska d. Haematologica. 2025 Jan 1;110(1):163-172. doi: 10.3324/haematol.2024.285645. Haematologica. 2025. PMID: 39021214 Free PMC article.